LOS ANGELES, CA / ACCESSWIRE / July 25, 2016 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA) announced today that its wholly owned subsidiary, Oxis Biotech Inc., has entered into an agreement with the University of Minnesota to develop and commercialize cancer therapies using Trispecific Killer Engager (TriKE) technology developed by researchers at the university to target NK cells to cancer.

Anthony J. Cataldo, Chief Executive Officer of Oxis, said the new agreement provides the company with a significant asset. He said TriKE technology is important because it’s highly effective at killing cancer cells with minimal side effects in pre-clinical models.

TriKE technology has several benefits compared to CAR-T therapy, which is known to be expensive and has been shown to carry significant side effects. Both Kite Pharma (Nasdaq:KITE) and Juno Therapeutics Inc. (Nasdaq:JUNO) have gained significant attention for their CAR-T efforts.

“The bispecific antibody platform is well known for its ability to kill cancer cells via antibody dependent cell-mediated toxicity (ADCC). However, current successes in immunotherapy indicate that enhanced killing will not be enough,” said Mr. Cataldo. “We believe the TriKE platform from University of Minnesota has found a way to expand the immune cell population within the patient, but not at the expense of creating a toxic environment.”

Jeffrey Miller, M.D., a professor of medicine and deputy director of the Masonic Cancer Center, University of Minnesota said, “The TriKE platform we have licensed to Oxis is designed to address the issue of making NK cells antigen specific by modifying a bispecific antibody platform and adding a third signal by inserting a modified IL-15 cross linker. IL-15 is known as a chief activator of NK cells that can enhance an anti-cancer immune response. This new trispecific platform is unique because it simultaneously delivers a priming, expansion, killing, and activating signal directly to the immune cell as it is in contact with the cancer cell. We are now working with Oxis to go forward with FDA approved clinical trials to demonstrate TriKE safety and efficacy. Unlike standard anti-cancer antibodies, we believe that TriKE can mediate specificity and deliver an immune expansion signal locally (instead of systemically) which has the potential to diminish toxicity.”

Daniel A. Vallera, Ph.D., a researcher and professor at the University of Minnesota said, “We are very excited to advance the TriKE technology in collaboration with Oxis.”

The medical journal Science Translational Medicine recently highlighted TriKE research by the University of Minnesota’s Vallera and Miller. Science Translational Medicine designated the research as an “Editors’ Choice,” and said “TriKEs were superior in restoring potent antigen-specific NK cell responses against AML targets and mediated robust and specific NK cell proliferation” (compared to bispecific killer engagers without the modified IL-15 linker).

ABOUT OXIS INTERNATIONAL, INC. – Oxis International, Inc., through a wholly owned subsidiary, Oxis Biotech, Inc., develops innovative drugs focused on the treatment of cancer and other unmet medical needs. Oxis’ lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 simultaneously targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug’s cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS’ lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.

FORWARD LOOKING STATEMENTS – Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company website: www.oxis.com

SOURCE: Oxis International, Inc.

ReleaseID: 442751

NEW YORK, NY / ACCESSWIRE / July 25, 2016 / Metanor Resources Inc. (TSX VENTURE: MTO) (OTC: MEAOF) (Frankfurt: M3R) is identified in a newly issued research report by Market Equities Research Group with several potential catalysts that exist in 2016 and 2017 with potential to result in $120 million market cap for MTO, translating to $0.28 per share — MTO is currently trading near 8 cents/share. This comprehensive report places a 12 month price target on shares of MTO.V at C$0.28 based on key valuation drivers which surround the Company executing on a strategy to increase sources of ore to feed to its 100%-owned Bachelor Gold Mill. MTO is currently focused on the Bachelor Lake underground mine and Barry open pit mine located in the prolific Abitibi region of central Quebec.

The full research report with chart, graphics, and analysis of value drivers may be found at
http://sectornewswire.com/report0722-2016MTO.pdf online.

– The Company states it is aiming “to open the access to more than 4 sources of ore to feed the Bachelor mill”, and is aiming for “mill throughput of between 1,500 and 2,000 TPD”. We expect higher-grade (between 6 g/T – 9 g/T) gold Hewfran sourced ore to come online this Summer-2016, plus there is potential production in 2017+ from a new 347,000 oz Au In-Pit resource at the Barry deposit (~116 km by road from mill) under an improved higher-grade (2+ g/T) model.

– MTO is actively growing high-grade gold ounces organically adjacent it’s Bachelor Mill, and at Barry it is looking to realize district-scale potential of its large land position and many untested targets along the Urban-Barry gold trend; Barry lies at the center of and directly on trend in the district, and is virtually surrounded with gold deposits and highly active and successful drilling programs (to the NE is Osisko, E is Bonterra, & Beaufield, N is Beaufield, & Urbana, SW is Osisko.& Beaufield).

– Potential to rationalize the district through ownership of its strategic 100%-owned Bachelor mill, with numerous local acquisition targets located within 100 km of the mill.

This latest gold bull run has seen smart money investors such as Eric Sprott (who recently increased his personal equity position in MTO to ~10% of shares outstanding, last purchasing shares on the open market near the current trading price and higher) accumulate shares of MTO, they understand that Metanor Resources offers potential for exceptional upside share price revaluation as a junior gold producer and explorer, our analysis concurs.

For the current year, Metanor has stated it expects to produce 40,000+ ounces of gold. MTO’s most recent available financials (ended March 31, 2016) revealed All-In cost of US$1,101 per ounce sold for the quarter ended (well below the current per oz price for gold). Clearly Metanor is on solid footing as a positive cash flow commercial gold producer and is undervalued; its book value currently sits at ~$52 million (>$0.12 cents per share), and infrastructure replacement value on all properties is in excess of $100 million, including a 100%-owned mill. MTO.V also offers a significant tax savings windfall value for a future acquirer with a loss-carry-forward on the books of close to $50 million, the impact could generate $15 million to $17 million in tax credits. MTO only has one debenture liability on the books remaining to be paid of $9 million, with a maturity date of August 2017.

The financial potential for the emerging Barry open pit mine will be investigated in the upcoming PEA analysis, to come shortly in September. The obvious future value that Barry offers MTO is apparent to us and we believe will soon be appreciated by the market place and reflected in higher share price revaluation.

When comparing the advanced stage of the Barry deposit with respect to other deposits / prospects in the Urban-Barry area; we see Bonterra now trading at a ~C$27 million market capitalization, with Beaufort trading at ~C$17million market capitalization — MTO now trades at a market cap of only ~$34 million and it is a healthy commercial gold producer with a 100%-owned mill. Certainly Metanor is due for upside revaluation on a comparative basis. We believe that the Barry deposit appears to have very strong potential to be production ready in 2017, following a PEA and perhaps a subsequent PFS. The recently released in-pit resource appears easily exploitable versus the underground resources of Bonterra’s resource. The exploration potential at Barry is also very highly compelling. While we believe that both Bonterra and Beaufield offer investors tremendous upside, there is in our view even more potential with MTO. With Eric Sprott recently increasing his ownership to near-10% of shares outstanding, this would appear to be a ringing endorsement of this potential.

When comparing the Barry deposit to Osisko’s Windfall deposit PEA and the costs it will take to bring the deposit to production, Windfall will need ~C$250 million to get a mine going with mill, the IRR is very low (~23%) on Windfall compared to an open pit mine scenario at Barry. In our analysis of what MTO’s upcoming Barry Mine PEA might look like, it is plain to us that the IRR on Barry is going to be phenomenal, possibly well over 100%, our calculations vary upwards of 200% depending on how some of the investment needed is treated (as possibly coming right out of working capital). The investment to take Barry to production is negligible, and the metrics are dramatically better now than when MTO last operated Barry; MTO shut Barry down when gold was at C$1,100/oz (now gold is near C$1,700/oz), the mill is better (was 82%, now it is 95 – 97% recoveries), transportation costs will be better, the shaft at Bachelor is no longer being rehabilitated, MTO is a more seasoned/experienced operator now, and MTO knows how to cut costs. Although we do not believe All-In Costs of C$1,200/oz gold will materialize (we expect much lower) from a new Barry open pit mine scenario, we used C$1,200 All-In for analysis should MTO focus its gold production efforts entirely on Barry (MTO can unilaterally shutter higher-cost Bachelor underground mine without penalty from Sandstorm as MTO has satisfied its US$20,000,000 cash flow guarantee, although juxtaposing Bachelor and Barry makes sense for better grade control); at current gold prices MTO would throw off C$500/oz profit, multiplied by 35,000 ounces per year = C$17,500,000/annum that MTO can use to grow larger, MTO can use the loss carry forward on the books to not pay any taxes on this, and such a scenario does not take into account the stated goal of the CEO to increase mill throughput. Forward discounting metrics dictate a much higher share price for MTO will materialize as such a scenario approaches fruition.

We believe a market capitalization closer to C$120 million ($0.28/share) for MTO is achievable near-term (within the next 12 months) as catalysts materialize that match the CEO’s recent stated objectives, and market awareness of the accomplishments underway are appreciated by the market place. This assessment is based on current gold prices near-US$1,300/oz, at US$1,600/oz gold, even higher revaluation is in order.

The signs at the Bachelor operation bode well for the future

– A well-developed, stable mining and milling operation at Bachelor.

– Excellent potential to combine the new Barry resource into the Bachelor Lake mine complex.

– A growing realization among the mining and investment community of the true potential of the Urban-Barry greenstone belt, with MTO’s Barry large property located in the heart of the district.

– The highly strategic Bachelor Mill located in proximity to the Urban-Barry area and also in proximity to several other known deposits as shown above.

As events unfold through 2016 and into 2017, we see strong potential for some very eventful news through this period.

The full research report with chart, graphics, and analysis of value drivers may be found at
http://sectornewswire.com/report0722-2016MTO.pdf online.

This release may contain forward-looking statements regarding future events that involve risk and uncertainties. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual events or results. Articles, excerpts, commentary and reviews herein are for information purposes and are not solicitations to buy or sell any of the securities mentioned.

Contact information:

Fredrick William, BA Ec.

Market Equities Research Group

f.william@marketequitiesresearch.com

SOURCE: Metanor Resources Inc.

ReleaseID: 442776

HENDERSON, NV / ACCESSWIRE / July 25, 2016 / Rainbow Coral Corp. (OTCQB: RBCC) partner company n3D has just inked a groundbreaking agreement with a leading preclinical contract research organization (CRO) to screen promising compound cancer via its revolutionary magnetic 3D bioprinting technology. The deal greatly expands n3D’s market reach and solidifies the company’s position as a potential leader in the bioprinting field.

SBH Biosciences (SBH) will use n3D’s cutting-edge bioprinting technology to make rapid and high-throughput
lead optimization tests (or assays) for compounds that will target often difficult oncology pathways. In addition to the cancer drug testing aspect, SBH will also offer n3D’s wound-healing assay model in its wide portfolio of tests as part of the venture.

“This is a very exciting arrangement with solid long-term prospects for n3D and our partner RBCC,” said n3D President and Chief Science Officer Glauco Souza. “We’ve broadened our already strong market presence and shown n3D’s life sciences technology leads the pack in the drug discovery, testing and development field. With this landmark agreement now in place, n3D is well positioned for further advances.”

RBCC CEO Kimberly Palmer hailed the new n3D/SBH deal. “n3D continues to show why it’s a well-respected innovator in the magnetic 3D printing market,” Palmer said. “Word has spread that the company has unique, forward-looking solutions that can help doctors and scientists solve the many medical problems facing the world today. We’re proud to be a partner with n3D and we can’t wait to see what the future holds for this agreement and the others sure to come.”

RBCC partner n3D most recently had a well-regarded article on magnetic 3D bioprinting published on a respected medical technology company’s website, garnering valuable publicity and prestige.

For more information on RBCC’s initiatives, please visit www.rainbowbiocorp.com.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit
www.rainbowbiocorp.com.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact:

Rainbow Coral Corp.

Kimberly Palmer, 702-940-2345

President and CEO

info@rainbowcoral.com

SOURCE: Rainbow Coral Corp.

ReleaseID: 442735

RENO, NV / ACCESSWIRE / July 25, 2016 / Renaissance Gold Inc. (“RenGold” or the “Company”) is pleased to announce that the Board of Directors has appointed Ronald L. Parratt to the office of President and Chief Executive Officer and Richard L. Bedell as Executive Vice President. Both Ron and Richard will continue as Directors of the Company. The return of Ron Parratt to RenGold’s management team will greatly enhance its efforts to identify exploration properties and attract joint venture partners at a time when there is increased interest in gold exploration in Nevada. Ron has played a significant role in a number of gold discoveries in Nevada over the past 35 years, most recently at Long Canyon as President and CEO of AuEx Ventures, Inc.

RenGold recently closed a private placement for gross proceeds of C$1,715,000. With the increased interest in the market sector in general and a healthier cash treasury, RenGold will focus over the next twelve months on upgrading its portfolio of exploration projects to attract earn-in funding partners. RenGold will also increase its generative exploration program to increase the property portfolio.

Commenting on the changes, Ron Parratt stated, “I look forward to continuing to execute our proven strategy and, in my new role, to more actively participate in identifying new exploration and corporate opportunities for the Company and to work in concert with Richard and the rest of our technical team.”

Richard L. Bedell adds,”With Ron overseeing the business of RenGold, I look forward to again focussing my efforts on the technical side of the business with more time to execute our motto, “Refining the Art of Mineral Exploration”. RenGold’s exploration team lives and works in Nevada, has superior understanding of Nevada geology, has built an extensive network of professional relationships, and can identify and secure properties in Nevada as well as anyone in the mining sector.”

About Renaissance Gold Inc.

Renaissance Gold Inc. is a gold/silver exploration company that has a large portfolio of exploration projects in Nevada and Utah. RenGold’s objective is to place the projects in exploration earn-in agreements with industry partners who provide exploration funding. RenGold applies the extensive exploration experience and high-end technical skills of its founders and team members to search for and acquire new precious metal exploration projects that are then offered for joint venture.

Renaissance Gold Inc.

By: Ronald L. Parratt, President and CEO

For further information, contact:

Ronald L. Parratt, 775-337-1545 or rparratt@rengold.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Renaissance Gold Inc.

ReleaseID: 442742